Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa

Inclusion Criteria: * Pathologic confirmation of invasive breast cancer * Stage: Clinical T1 \>/= 1.0 cm, T2 or T3, N0-3, M0 * HER2 negative * ER and PgR status by immunohistochemistry must be known. ER positive patients are allowed if physicain has determined neoadjuvant chemo is appropriate. * Life expectancy greater than six months * Use of an effective means of contraception is required Exclusion Criteria: * Pregnant or breastfeeding * Prior anthracycline or platinum based therapy * Prior treatment for the current breast cancer, including chemotherapy, hormonal therapy, radiation or experimental therapy * Ipsilateral breast recurrence, unless prior treatment consisted of excision alone for DCIS or breast-conserving treatment and hormonal therapy for DCIS or invasive cancer * Peripheral neuropathy of any etiology that exceeds grade 1 * Significant hearing loss * Renal dysfunction * Use of other investigational or study agents * History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs * Uncontrolled intercurrent illness * Any condition that would prohibit administration of corticosteroids * Uncontrolled diabetes * Pre-existing medical condition that would represent toxicity in excess of grade 1 as measured by CTCAE (unless not considered medically significant by the physician) * Known HIV positive individuals on combination antiretroviral therapy